IRWD:NSD-Ironwood Pharmaceuticals Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 11.14

Change

-0.06 (-0.54)%

Market Cap

USD 1.80B

Volume

1.88M

Avg Analyst Target

USD 14.00 (+25.67%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Ironwood Pharmaceuticals Inc (IRWD) Stock Analysis:
Based on the Ironwood Pharmaceuticals Inc stock forecasts from 1 analysts, the average analyst target price for Ironwood Pharmaceuticals Inc is USD 14.00 over the next 12 months. Ironwood Pharmaceuticals Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Ironwood Pharmaceuticals Inc is Slightly Bullish , which is based on 10 positive signals and 6 negative signals. At the last closing, Ironwood Pharmaceuticals Inc’s stock price was USD 11.14. Ironwood Pharmaceuticals Inc’s stock price has changed by +0.20% over the past week, -0.73% over the past month and +9.32% over the last year.

About

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipati ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-25 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
NBIX Neurocrine Biosciences Inc

+0.07 (+0.09%)

USD7.20B 16.70 37.25
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
ITCI Intra-Cellular Therapies Inc

+2.30 (+5.19%)

USD3.92B N/A N/A
PCRX Pacira BioSciences Inc

-1.45 (-2.29%)

USD2.82B 46.64 19.70
TLRY Tilray Inc

-0.12 (-2.05%)

USD2.70B N/A N/A
CGC Canopy Growth Corporation

-0.04 (-0.54%)

USD2.66B N/A N/A
SUPN Supernus Pharmaceuticals Inc

+0.56 (+1.92%)

USD1.55B 19.32 9.45
DVAX Dynavax Technologies Corporati..

N/A

USD1.51B N/A 98.57

ETFs Containing IRWD

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.46% 80% B- 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.46% 80% B- 57% F
Trailing 12 Months  
Capital Gain 9.32% 91% A- 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.32% 91% A- 72% C-
Trailing 5 Years  
Capital Gain -20.14% 70% C- 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.14% 68% D+ 25% F
Average Annual (5 Year Horizon)  
Capital Gain -4.94% 41% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.94% 39% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 22.60% 88% B+ 69% D+
Risk Adjusted Return -21.87% 38% F 15% F
Market Capitalization 1.80B 93% A 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 3.39 79% C+ 87% B+
Price/Book Ratio 3.12 46% F 39% F
Price / Cash Flow Ratio 10.67 19% F 33% F
EV/EBITDA 7.38 73% C 71% C-
Management Effectiveness  
Return on Equity 18.10% 92% A- 83% B
Return on Invested Capital 38.54% 96% A 95% A
Return on Assets 19.21% 100% A+ 98% A+
Debt to Equity Ratio 686.87% 7% F 3% F
Technical Ratios  
Short Ratio 8.06 16% F 8% F
Short Percent 19.47% 7% F 8% F
Beta 1.21 39% F 42% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector